Integrated Dna Technologies, Inc.

Nicole Mary Bode

Mark Aaron Behlke

Christopher Anthony Vakulskas

Michael Allen Collingwood

Garrett Richard Rettig

Kristin Beltz

Liyang Zhang

The present disclosure concerns polynucleotides and amino acids of. Cas12a (Cpf1) and methods for their use for genome editing in eukaryotic cells.

Methods using novel CPF1 mutations that enhance the DNA cleavage activity ofsp. CPF1

This invention pertains to mutant Cas9 nucleic acids and proteins for use in CRISPR/Cas endonuclease systems, and their methods of use. In particular, the invention pertains to an isolated mutant Cas9 protein, wherein the isolated mutant Cas9 protein is active in a CRISPR/Cas endonuclease system, wherein the CRISPR/Cas endonuclease system displays reduced off-target editing activity and maintained on-target editing activity relative to a wild-type CRISPR/Cas endonuclease system. The invention also includes isolated nucleic acids encoding mutant Cas9 proteins, ribonucleoprotein complexes and CRSPR/Cas endonuclease systems having mutant Cas9 proteins that display reduced off-target editing activity and maintained on-target editing activity relative to a wild-type CRISPR/Cas endonuclease system.

Cas9 mutant genes and polypeptides encoded by same

The present disclosure concerns polynucleotides and amino acids ofsp. Cas12a (Cpf1) and methods for their use for genome editing in eukaryotic cells.

[object Object]

This invention pertains to mutant Cas9 nucleic acids and proteins for use in CRISPR/Cas endonuclease systems, and their methods of use. In particular, the invention pertains to an isolated mutant Cas9 protein, wherein the isolated mutant Cas9 protein is active in a CRISPR/Cas endonuclease system, wherein the CRISPR/Cas endonuclease system displays reduced off-target editing activity and maintained on-target editing activity relative to a wild-type CRISPR/Cas endonuclease system. The invention also includes isolated nucleic acids encoding mutant Cas9 proteins, ribonucleoprotein complexes and CRISPR/Cas endonuclease systems having mutant Cas9 proteins that display reduced off-target editing activity and maintained on-target editing activity relative to a wild-type CRISPR/Cas endonuclease system.

Growing community of inventors

Oxford, IA, United States of America

Nicole Mary Bode